SCHEMBL2125753

SCHEMBL2125753

O=S(O)S(=O)O.O=S(O)S(=O)O.[Na]

nearest known ligand 0.56

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29489533 1.00
SCHEMBL1133571 0.94 CA1 (0.62) CA1CA2
SCHEMBL1011 0.94
SCHEMBL301246 0.88
SCHEMBL18394416 0.88
SCHEMBL8087374 0.88
Ammonia Solution, Strong SCHEMBL11247301 0.88
Ammonia Solution, Strong SCHEMBL246874 0.88
Sulfurous Acid SCHEMBL8764712 0.88 CA1 (0.75) CA1CA2
SCHEMBL9662551 0.88

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150352020-A1 COMPOSITIONS AND METHODS FOR PRODUCING STABLE NEGATIVE OXIDATION REDUCTION POTENTIAL IN CONSUMABLE MATERIALS MILJKOVIC DUSAN (US) 2015-12-10 US disclosed
US-9144581-B2 Compositions and methods for producing stable negative oxidation reduction potential in consumable materials MILJKOVIC DUSAN (US) 2015-09-29 US disclosed
EP-2896302-A2 FOOD COMPOSITION COMPRISING MAGNESIUM METAL PARTICLES Miljkovic, Dusan (US) 2015-07-22 EP disclosed
US-20150132359-A1 COMPOSITIONS AND METHODS FOR PRODUCING STABLE NEGATIVE OXIDATION REDUCTION POTENTIAL IN CONSUMABLE MATERIALS MILJKOVIC DUSAN (US) 2015-05-14 US disclosed
EP-2442674-B1 COMPOSITIONS AND METHODS FOR PRODUCING STABLE NEGATIVE OXIDATION REDUCTION POTENTIAL IN CONSUMABLE MATERIALS MILJKOVIC DUSAN (US) 2015-03-04 EP disclosed
US-8852660-B2 Compositions and methods for producing stable negative oxidation reduction potential in consumable materials MILJKOVIC DUSAN (US) 2014-10-07 US disclosed
EP-2442674-A2 COMPOSITIONS AND METHODS FOR PRODUCING STABLE NEGATIVE OXIDATION REDUCTION POTENTIAL IN CONSUMABLE MATERIALS Miljkovic, Dusan (US) 2012-04-25 EP disclosed
WO-2010147751-A2 COMPOSITIONS AND METHODS FOR PRODUCING STABLE NEGATIVE OXIDATION REDUCTION POTENTIAL IN CONSUMABLE MATERIALS MILJKOVIC DUSAN (US) 2010-12-23 WO disclosed
US-20100316776-A1 COMPOSITIONS AND METHODS FOR PRODUCING STABLE NEGATIVE OXIDATION REDUCTION POTENTIAL IN CONSUMABLE MATERIALS MILJKOVIC DUSAN 2010-12-16 US disclosed
EP-1515972-B1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY HOFFMANN LA ROCHE (CH) 2009-05-13 EP disclosed
CN-100361992-C Sulfonamide substituted xanthine derivatives for use as PEPCK inhibitors HOFFMANN LA ROCHE (CH) 2008-01-16 CN disclosed
US-7148229-B2 Sulfonamide substituted xanthine derivatives HOFFMAN-LA ROCHE INC. (US) 2006-12-12 US disclosed
US-7135475-B2 Antidiabetic agents HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
CN-1751044-A Sulfonamide substituted xanthine derivatives for use as PEPCK inhibitors HOFFMANN LA ROCHE (CH) 2006-03-22 CN disclosed
EP-1599477-A1 SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-11-30 EP disclosed
EP-1515972-A1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2005-03-23 EP disclosed
US-20040192708-A1 Sulfonamide substituted xanthine derivatives DUNTEN PETER W (US) 2004-09-30 US disclosed
WO-2004074288-A1 SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-09-02 WO disclosed
US-20040014766-A1 Amide substituted xanthine derivatives HOFFMANN-LA ROCHE INC. 2004-01-22 US disclosed
WO-2003106459-A1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014766-A1 Amide substituted xanthine derivatives GYS2, GLS2, PYGL CA1 2165/4885CA2 1606/4885
US-20040192708-A1 Sulfonamide substituted xanthine derivatives GYS2, SLC5A1, SLC5A2 CA1 1907/4885CA2 1317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.